J Clin Endocrinol Metab. 2023 Apr 3:dgad188. doi: 10.1210/clinem/dgad188. Online ahead of print.
ABSTRACT
CONTEXT: Challenges do exist in the management of GCK-MODY, especially during pregnancy.
OBJECTIVE: To evaluate prevalence of congenital anomaly in new-borns from GCK-MODY mothers, and the relationship between fetus genotype and the risk of congenital malformation as well as other adverse pregnancy outcomes.
DATA SOURCES: The electronic databases including PubMed, EMBASE, and Cochrane database last updated on July 16nd, 2022 were searched.
STUDY SELECTION: We included observational studies conducted in GCK-MODY complicated with pregnancy, and reporting at least one of the pregnancy outcome.
DATA EXTRACTION: We extracted data in duplicate and the risk of bias was evaluated by Newcastle-Ottawa Quality Assessment Scale (NOS). All the statistical analysis was performed by Cochrane Review Manager.
RESULTS: Eight studies were selected in the meta-analysis. Five were of high quality and 3 were of medium quality evaluated by NOS. A total of 257 GCK-MODY mothers and 499 offsprings were enrolled. Among them, 370 offsprings were divided into two group: GCK affected offspring (GCK+, n=238) and GCK unaffected offspring (GCK-, n=132). The percentage of congenital malformations in GCK pregnant women’s offspring was 2.4%. The risk of congenital malformations was similar between GCK+ and GCK- group (OR=0.56, 95%CI 0.07-4.51, I2=0%, P=0.59). The risk of macrosomia/LGA, neonatal hypoglycemia and combined adverse neonatal outcome was significantly lower in offsprings with GCK mutation compared with non GCK mutation carriers.
CONCLUSIONS: The percentage of congenital malformations was 2.4% in GCK pregnant women’s offsprings, and the new-borns with GCK mutation have lower birth complication than non GCK mutation carriers.
PMID:37011183 | DOI:10.1210/clinem/dgad188
